Cover Image
市場調查報告書

EpiCast Report:多發性骨髓瘤的流行病學預測 2023年

EpiCast Report: Multiple Myeloma - Epidemiology Forecast to 2023

出版商 GlobalData 商品編碼 336858
出版日期 內容資訊 英文 43 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:多發性骨髓瘤的流行病學預測 2023年 EpiCast Report: Multiple Myeloma - Epidemiology Forecast to 2023
出版日期: 2015年10月05日 內容資訊: 英文 43 Pages
簡介

全球主要8市場 (美國、法國、德國、義大利、西班牙、英國、日本、中國都市區) 的多發性骨髓瘤 (MM) 的診斷病例數,預計從2013年到2023年以4.39%的年成長率發展,從2013年的6萬7,557件到2023年達到9萬7,225件。

本報告提供全球主要8市場上多發性骨髓瘤 (MM) 的診斷病例數及死亡人數的變遷的相關調查、疾病的背景、風險要素和並存症、各年齡、性別、重症度、原因病原的診斷病例數及死亡人數的預測等相關彙整。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 風險要素與並存症
  • 全球趨勢
    • 發病率
    • 多發性骨髓瘤 (MM) 的存活率:主要8市場
  • 預測手法
    • 使用來源
    • 未使用來源
    • 預測的前提條件、手法:多發性骨髓瘤 (MM) 的診斷病例
    • 預測的前提條件、手法:多發性骨髓瘤 (MM) 的5年間患病診斷病例
    • 預測的前提條件、手法:多發性骨髓瘤 (MM) 診斷時的臨床階段
  • 多發性骨髓瘤 (MM) 的流行病學的預測
    • 診斷病例數
    • 診斷病例數:各年齡
    • 診斷病例數:性別
    • 標準診斷案例數:各年齡
    • 診斷時的臨床階段
    • 5年間患病診斷病例數
  • 檢驗
    • 流行病學預測的考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

  • 參考資料
  • 關於作者
  • 關於GlobalData
  • 關於EpiCast
  • 免責聲明

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER083-15

Multiple myeloma is a hematologic cancer of the white blood cell; more specifically, multiple myeloma is a cancer of the plasma cell. Normal plasma cells help fight infections by making antibodies that recognize and attack germs, but multiple myeloma causes cancer cells to accumulate in the bone marrow where they crowd out healthy blood cells, impairing their ability to fight infections. Rather than producing helpful antibodies, the cancer cells produce abnormal proteins called monoclonal (M) proteins that can impair kidney functions.

GlobalData epidemiologists forecast the diagnosed incident and five-year diagnosed prevalent cases of multiple myeloma in the 8MM. GlobalData epidemiologists forecast an increase in the diagnosed incident cases of multiple myeloma in the 8MM, from 67,557 diagnosed incident cases in 2013 to 97,225 diagnosed incident cases in 2023, with an Annual Growth Rate (AGR) of 4.39% during the forecast period. The five-year diagnosed prevalent cases of multiple myeloma in the 8MM are expected to increase from 168,750 diagnosed prevalent cases in 2013 to 236,866 diagnosed prevalent cases in 2023, with an AGR of 4.04% during the forecast period. The increase in the diagnosed five-year prevalent cases of multiple myeloma is partly attributed to the moderately rising trend in the incidence of multiple myeloma in the 8MM, combined with changes in the population demographics in the respective markets.

GlobalData's forecast is supported by at least 10 years of robust, country-specific historical data obtained from the WHO International Agency for Cancer Research's (IARC's) SurvCan, the Surveillance of Epidemiology and End Results Program Cancer Statistics Review 1975-2009, EUROCARE-4, research articles published in peer-reviewed journals, and the IARC's Cancer Incidence in Five Continents Plus database, which provided detailed case segmentation by age and sex and is considered the gold standard for international comparison of country-specific data. Another strength of this analysis is that GlobalData epidemiologists compared the incident case projections with the estimates made by country-specific registries and the IARC, and found that the forecast numbers were in accordance with the international estimates.

Scope

  • The Multiple Myleoma EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for multiple myeloma in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and urban China). The series includes a 10-year epidemiological forecast for diagnosed incident and total prevalent cases of monoclonal gammopathy of undetermined significance (MGUS) cases, segmented by age and sex. It also includes a 10-year forecast for diagnosed incident cases of multiple myeloma, segmented by age (in five-year increments beginning at 40 years and ending at =85 years), sex, and stage at clinical diagnosis, as well as a 10-year epidemiological forecast for the five-year diagnosed prevalent cases of multiple myeloma in these markets.
  • The Multiple Myeloma epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The Multiple Myeloma EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global multiple myeloma market.
  • Quantify patient populations in the global multiple myeloma market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for multiple myeloma therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. 4.3.1 Incidence
    • 3.3.2. Survival Rates for MM - 8MM
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods, MM Diagnosed Incident Cases
    • 3.4.4. Forecast Assumptions and Methods, MM Five-Year Diagnosed Prevalent Cases
    • 3.4.5. Forecast Assumptions and Methods, MM Clinical Stages at Diagnosis
  • 3.5. Epidemiological Forecast for MM (2013-2023)
    • 3.5.1. Diagnosed Incident Cases of MM
    • 3.5.2. Age-Specific Diagnosed Incident Cases of MM
    • 3.5.3. Sex-Specific Diagnosed Incident Cases of MM
    • 3.5.4. Age-Standardized Diagnosed Incidence of MM
    • 3.5.5. Diagnosed Incident Cases of MM by Clinical Stage at Diagnosis
    • 3.5.6. Five-Year Diagnosed Prevalent Cases of MM
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: MM Clinical Stages at Diagnosis, Using the ISS Criteria
  • Table 2: Risk Factors and Comorbidities for MM
  • Table 3: Trends in the Age-Adjusted Incidence of MM in the US, Ages ≥40 Years, 1993-2007
  • Table 4: Trends in the Age-Adjusted Incidence of MM in the 5EU, Ages ≥40 Years, 1993-2007
  • Table 5: Trends in the Age-Adjusted Incidence of MM in Japan, Ages ≥40 Years, 1993-2007
  • Table 6: Trends in the Age-Adjusted Incidence of MM in Urban China, Ages ≥40 Years, 1993-2007
  • Table 7: Trends in the Five-Year Relative Survival (%) of MM in the 8MM, Both Sexes, 1993-2009
  • Table 8: 8MM, Sources of Epidemiological Data Used for the Forecast for MM Diagnosed Incident Cases
  • Table 9: 8MM, Sources of Epidemiological Data Used for the Forecast for MM Diagnosed Five-Year Prevalent Cases
  • Table 10: 8MM, Sources of Epidemiological Data Used for the Segmentation of MM Incident Cases by Clinical Stage at Diagnosis
  • Table 11: 8MM, Diagnosed Incident Cases of MM, Both Sexes, Ages ≥40 Years, N, 2013-2023
  • Table 12: 8MM, Age-Specific Diagnosed Incident Cases of MM, Both Sexes, N (Row %), 2013
  • Table 13: 8MM, Sex-Specific Diagnosed Incident Cases of MM, Ages ≥40 Years, N (Row %), 2013
  • Table 14: 8MM, Five-Year Diagnosed Prevalent Cases of MM, Both Sexes, Ages ≥40 Years, N, 2013-2023

List of Figures

  • Figure 1: 8MM, Diagnosed Incident Cases of MM, Both Sexes, Ages ≥40 Years, N, 2013-2023
  • Figure 2: 8MM, Age-Specific Diagnosed Incident Cases of MM, Both Sexes, N, 2013
  • Figure 3: 8MM, Sex-Specific Diagnosed Incident Cases of MM, Ages ≥40 Years, N, 2013
  • Figure 4: 8MM, Age-Standardized Diagnosed Incidence of MM (Cases per 100,000 Population), Ages ≥40 Years, by Sex, 2013
  • Figure 5: 8MM, Diagnosed Incident Cases of MM by Clinical Stage at Diagnosis, Ages ≥40 Years, N, 2013
  • Figure 6: 8MM, Five-Year Diagnosed Prevalent Cases of MM, Both Sexes, Ages ≥40 Years, N, 2013-2023
Back to Top